Baxter price target lowered to $37 from $38 at Citi

Citi lowered the firm’s price target on Baxter to $37 from $38 and keeps a Neutral rating on the shares as part of a Q2 earnings preview for the U.S. medical technology space. While Citi anticipates that investors will “continue to lean into quality names that have consistently beat and raised,” with the significant reset in valuations across the group there is “opportunity across the cap stack,” the analyst tells investors in a research note.